256 related articles for article (PubMed ID: 35057550)
41. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
[TBL] [Abstract][Full Text] [Related]
42. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
[TBL] [Abstract][Full Text] [Related]
43. Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
Jiang S; Chang H; Deng S; Fan D
Int J Oncol; 2019 Jun; 54(6):1933-1942. PubMed ID: 31081049
[TBL] [Abstract][Full Text] [Related]
44. Mycotoxin verrucarin A inhibits proliferation and induces apoptosis in prostate cancer cells by inhibiting prosurvival Akt/NF-kB/mTOR signaling.
Liu Y; Gao X; Deeb D; Zhang Y; Shaw J; Valeriote FA; Gautam SC
J Exp Ther Oncol; 2016 Nov; 11(4):251-260. PubMed ID: 27849335
[TBL] [Abstract][Full Text] [Related]
45. Juniperus indica Bertol. extract synergized with cisplatin against melanoma cells via the suppression of AKT/mTOR and MAPK signaling and induction of cell apoptosis.
Huang XF; Gao HW; Lee SC; Chang KF; Tang LT; Tsai NM
Int J Med Sci; 2021; 18(1):157-168. PubMed ID: 33390784
[No Abstract] [Full Text] [Related]
46. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
Makhlin I; Zhang J; Long CJ; Devarajan K; Zhou Y; Klein-Szanto AJ; Huang M; Chernoff J; Boorjian SA
BJU Int; 2011 Jul; 108(2 Pt 2):E84-90. PubMed ID: 21050361
[TBL] [Abstract][Full Text] [Related]
47. Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.
Gao X; Liu J; Fan D; Li X; Fang Z; Yan K; Fan Y
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34935059
[TBL] [Abstract][Full Text] [Related]
48. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
49. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
50. δ-tocotrienol induces human bladder cancer cell growth arrest, apoptosis and chemosensitization through inhibition of STAT3 pathway.
Ye C; Zhao W; Li M; Zhuang J; Yan X; Lu Q; Chang C; Huang X; Zhou J; Xie B; Zhang Z; Yao X; Yan J; Guo H
PLoS One; 2015; 10(4):e0122712. PubMed ID: 25849286
[TBL] [Abstract][Full Text] [Related]
51. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.
Moon du G; Lee SE; Oh MM; Lee SC; Jeong SJ; Hong SK; Yoon CY; Byun SS; Park HS; Cheon J
Int J Oncol; 2014 Sep; 45(3):1027-35. PubMed ID: 24969552
[TBL] [Abstract][Full Text] [Related]
52. Olive mill wastewater and hydroxytyrosol inhibits atherogenesis in apolipoprotein E-deficient mice.
Hara T; Fukuda D; Ganbaatar B; Pham PT; Aini K; Rahadian A; Suto K; Yagi S; Kusunose K; Yamada H; Soeki T; Sata M
Heart Vessels; 2023 Nov; 38(11):1386-1394. PubMed ID: 37462755
[TBL] [Abstract][Full Text] [Related]
53. Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor.
Yoshino H; Yokoyama S; Tamai M; Okamura S; Iizasa S; Sakaguchi T; Osako Y; Inoguchi S; Matsushita R; Yamada Y; Nakagawa M; Tatarano S; Tanimoto A; Enokida H
FEBS Open Bio; 2023 Jun; 13(6):1056-1066. PubMed ID: 37079001
[TBL] [Abstract][Full Text] [Related]
54. Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3β.
Gerhardt D; Bertola G; Dietrich F; Figueiró F; Zanotto-Filho A; Moreira Fonseca JC; Morrone FB; Barrios CH; Battastini AM; Salbego CG
Urol Oncol; 2014 Jan; 32(1):36.e1-9. PubMed ID: 24239461
[TBL] [Abstract][Full Text] [Related]
55. Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
Pinto-Leite R; Arantes-Rodrigues R; Palmeira C; Gaivão I; Cardoso ML; Colaço A; Santos L; Oliveira P
J Toxicol Environ Health A; 2012; 75(13-15):788-99. PubMed ID: 22788366
[TBL] [Abstract][Full Text] [Related]
56. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
Grivas PD; Day KC; Karatsinides A; Paul A; Shakir N; Owainati I; Liebert M; Kunju LP; Thomas D; Hussain M; Day ML
Mol Med; 2013 Nov; 19(1):367-76. PubMed ID: 24166682
[TBL] [Abstract][Full Text] [Related]
58. miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness.
Zhang Q; Zhuang J; Deng Y; Yang L; Cao W; Chen W; Lin T; Lv X; Yu H; Xue Y; Guo H
Theranostics; 2017; 7(19):4777-4790. PubMed ID: 29187903
[No Abstract] [Full Text] [Related]
59. Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway.
Li Y; Huang X; Huang Z; Feng J
Cell Biochem Biophys; 2014 Nov; 70(2):1337-42. PubMed ID: 24902539
[TBL] [Abstract][Full Text] [Related]
60. RNA silencing of integrin-linked kinase increases the sensitivity of the A549 lung cancer cell line to cisplatin and promotes its apoptosis.
Zhao X; Xu Z; Wang Z; Wu Z; Gong Y; Zhou L; Xiang Y
Mol Med Rep; 2015 Jul; 12(1):960-6. PubMed ID: 25760437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
